BRCA2 Mutation: Poor Prognosis in Prostate Cancer

The study, published in the British Journal of Cancer, observed poor survival at the end of the follow-up period in men carrying the mutation, compared to non-carriers.

BRCA2

Among men with prostate cancer detected on screening, survival among those with a mutation in the gene is much poorer than in those without such a mutation, researchers report.

BRCA2

British Journal of Cancer

The findings suggest that mutation carriers may warrant additional treatments to improve their prognosis, say Steven Narod (Women’s College Hospital, Toronto, Ontario) and fellow authors writing in the .

BRCA2

BRCA2

mutations are known to confer an increased risk for developing prostate cancer and also to be associated with more aggressive tumours. However, the effect of mutations status on mortality in the setting of screen-detected cancers is unclear.

Original report: http://bit.ly/1yRJII4

Source: medwireNews